Beyond type 2 diabetes: sodium glucose co‐transporter‐inhibition in type 1 diabetes

Volume: 21, Issue: S2, Pages: 53 - 61
Published: Apr 1, 2019
Abstract
Use of sodium glucose cotransporter (SGLT) inhibitors are a well-established therapeutic option in type 2 diabetes (T2D) with a variety of proven therapeutic benefits. They have become a pillar of current treatment guidelines. In type 1 diabetes (T1D), initial exploratory studies have shown benefits in glycemic control, weight control, and cardiovascular risk parameters, leading to trials aiming for regulatory submission with several agents....
Paper Details
Title
Beyond type 2 diabetes: sodium glucose co‐transporter‐inhibition in type 1 diabetes
Published Date
Apr 1, 2019
Volume
21
Issue
S2
Pages
53 - 61
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.